…Innovative Tools In Choice Basket
CATHERINE MUROMBEDZI
HEALTH CORRESPONDENT
The HIV Research for Prevention Conference (HIVR4P) in Lima, Peru, ran from the 6th to the 10th of October, 2024. This global scientific gathering saw 1,500 participants from 78 countries, fostering collaboration and knowledge sharing to address the region’s unique challenges.
Focus on HIV Prevention and Research is important as it is a pillar to ending HIV/AIDS by 2030.

Latin America urgently needs the spotlight on its HIV prevention efforts. New HIV acquisitions increased by 9% between 2010 and 2023. This growth is alarming, especially considering the global advancements in HIV prevention.
Beatriz Grinsztejn, President of the International AIDS Society (IAS), emphasized the importance of scaling up HIV prevention efforts across Latin America.
“By holding the conference in Lima, we hope to draw attention to the urgent need to scale up HIV prevention efforts across Latin America,” Grinsztejn said.
In 2023, globally, approximately 1.3 million people were newly infected with HIV. (UNAIDS)
To break it down further, every week, 4 000 adolescent girls and young women aged 15-24 years became infected with HIV.
It is worth noting that while significant progress has been made in reducing new HIV infections globally, some regions continue to face challenges. In Latin America, for example, new HIV infections increased by 9% between 2010 and 2023.
Eight countries in the region experienced increases in new HIV infections since 2015.
Argentina, Bolivia, Brazil, Colombia, Dominican Republic, Honduras, Mexico, and Peru recorded a rise in new infections. The infections were high among vulnerable populations. Sixty six percent of new HIV infections in 2022 were among key populations and their sex partners.
Delays in implementing global recommendations on PrEP and treatment optimisation have hindered reducing new HIV infections and AIDS-related mortality.
Although Latin American countries have made significant progress in expanding access to HIV treatment, with the numbers of AIDS-related deaths decreasing by 32% since 2010, the new infections are still too high.
The HIVR4P conference focuses on HIV prevention research, encompassing HIV vaccines, microbicides, pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP) and biomedical interventions.
HIV treatment works as prevention. An HIV+ person taking antiretroviral therapy (ART) as prescribed, and with the treatment working well gets virally suppressed. When virally suppressed, the chances of passing the virus are minimal. The virus becomes undetected. When undetected, the virus is untransmitable U=U.
PrEP and PEP as preventive measures are effective when correctly used.
PrEP is a daily medication for HIV-negative individuals at high risk of infection, preventing HIV by 92-99%. Eligible groups include sexually active individuals, injection drug users, sex workers, and those with HIV-positive partners (discordant relationships).
PEP is an emergency medication taken within 72 hours of potential HIV exposure, reducing transmission risk by 80%. Eligible individuals include those with recent exposure, occupational exposure, or sexual assault.
Exciting updates were shared at the conference, with Lenacapavir being topical.
Its efficacy at 96%, coupled with safety in preventing HIV took away the pill burden. Lenacapavir is a 6-monthly injectable.
The choice basket for females got strengthened. The dapivirine ring is a discreet vaginal ring that is inserted, releasing protection for 28 days.
The Medicines Control Authority of Zimbabwe (MCAZ) approved its use in 2022. It awaits funding to roll out. The 28-day tool has been bettered, and now a three-month version of the ring demonstrated pharmacokinetic superiority.
For another prevention choice, Long-acting Cabotegravir (CAB-LA). Despite approval, access remains limited.
Zimbabwe is piloting a year study in six sites running up to May 2025.
Zimbabwe is one of the countries to have undertaken in the clinical trials from 2018 to 2021.
In Zimbabwe, oral PrEP is available. However, there is a knowledge gap among the general population with Civil Society Organisations (CSO) urged to amplify the prevention messages.
The Lima Conference noted PrEP access remained low in Latin America, with only 46 000 users among 430 million people.
Researchers are developing diverse HIV prevention methods, including gels, patches, injections, douches, pills, rings, films.
These prevention tools are to be used in combination for effectiveness.
The HIVR4P conference highlights significant advancements in HIV prevention research. While breakthroughs like lenacapavir and dapivirine vaginal ring offer hope, access constraints persist.
Grinsztejn, President of the IAS, emphasized the importance of scaling up HIV prevention efforts across Latin America. By holdingf the conference in Lima, the hope is to draw attention to this urgent need and spark meaningful action.
With the exclusive use of English as the language of communication, this became a barrier to effective communication in the global fight against HIV/AIDS.
The exclusive use of English has raised concerns about limiting participation from host and neighbouring countries. In future, to ensure inclusive participation, organisers should provide simultaneous interpretation services in Spanish, Portuguese, French and other languages.
Additionally, conference materials and abstracts should be translated into multiple languages to facilitate knowledge sharing and collaboration among researchers, advocates, and policymakers from diverse linguistic backgrounds.
By bridging the language gap, the conference can better serve the HIV prevention needs of Latin America and beyond.
● Feedback: [email protected]

